Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.
Conti DV., Darst BF., Moss LC., Saunders EJ., Sheng X., Chou A., Schumacher FR., Olama AAA., Benlloch S., Dadaev T., Brook MN., Sahimi A., Hoffmann TJ., Takahashi A., Matsuda K., Momozawa Y., Fujita M., Muir K., Lophatananon A., Wan P., Le Marchand L., Wilkens LR., Stevens VL., Gapstur SM., Carter BD., Schleutker J., Tammela TLJ., Sipeky C., Auvinen A., Giles GG., Southey MC., MacInnis RJ., Cybulski C., Wokołorczyk D., Lubiński J., Neal DE., Donovan JL., Hamdy FC., Martin RM., Nordestgaard BG., Nielsen SF., Weischer M., Bojesen SE., Røder MA., Iversen P., Batra J., Chambers S., Moya L., Horvath L., Clements JA., Tilley W., Risbridger GP., Gronberg H., Aly M., Szulkin R., Eklund M., Nordström T., Pashayan N., Dunning AM., Ghoussaini M., Travis RC., Key TJ., Riboli E., Park JY., Sellers TA., Lin H-Y., Albanes D., Weinstein SJ., Mucci LA., Giovannucci E., Lindstrom S., Kraft P., Hunter DJ., Penney KL., Turman C., Tangen CM., Goodman PJ., Thompson IM., Hamilton RJ., Fleshner NE., Finelli A., Parent M-É., Stanford JL., Ostrander EA., Geybels MS., Koutros S., Freeman LEB., Stampfer M., Wolk A., Håkansson N., Andriole GL., Hoover RN., Machiela MJ., Sørensen KD., Borre M., Blot WJ., Zheng W., Yeboah ED., Mensah JE., Lu Y-J., Zhang H-W., Feng N., Mao X., Wu Y., Zhao S-C., Sun Z., Thibodeau SN., McDonnell SK., Schaid DJ., West CML., Burnet N., Barnett G., Maier C., Schnoeller T., Luedeke M., Kibel AS., Drake BF., Cussenot O., Cancel-Tassin G., Menegaux F., Truong T., Koudou YA., John EM., Grindedal EM., Maehle L., Khaw K-T., Ingles SA., Stern MC., Vega A., Gómez-Caamaño A., Fachal L., Rosenstein BS., Kerns SL., Ostrer H., Teixeira MR., Paulo P., Brandão A., Watya S., Lubwama A., Bensen JT., Fontham ETH., Mohler J., Taylor JA., Kogevinas M., Llorca J., Castaño-Vinyals G., Cannon-Albright L., Teerlink CC., Huff CD., Strom SS., Multigner L., Blanchet P., Brureau L., Kaneva R., Slavov C., Mitev V., Leach RJ., Weaver B., Brenner H., Cuk K., Holleczek B., Saum K-U., Klein EA., Hsing AW., Kittles RA., Murphy AB., Logothetis CJ., Kim J., Neuhausen SL., Steele L., Ding YC., Isaacs WB., Nemesure B., Hennis AJM., Carpten J., Pandha H., Michael A., De Ruyck K., De Meerleer G., Ost P., Xu J., Razack A., Lim J., Teo S-H., Newcomb LF., Lin DW., Fowke JH., Neslund-Dudas C., Rybicki BA., Gamulin M., Lessel D., Kulis T., Usmani N., Singhal S., Parliament M., Claessens F., Joniau S., Van den Broeck T., Gago-Dominguez M., Castelao JE., Martinez ME., Larkin S., Townsend PA., Aukim-Hastie C., Bush WS., Aldrich MC., Crawford DC., Srivastava S., Cullen JC., Petrovics G., Casey G., Roobol MJ., Jenster G., van Schaik RHN., Hu JJ., Sanderson M., Varma R., McKean-Cowdin R., Torres M., Mancuso N., Berndt SI., Van Den Eeden SK., Easton DF., Chanock SJ., Cook MB., Wiklund F., Nakagawa H., Witte JS., Eeles RA., Kote-Jarai Z., Haiman CA.
Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants. The top genetic risk score (GRS) decile was associated with odds ratios that ranged from 5.06 (95% confidence interval (CI), 4.84-5.29) for men of European ancestry to 3.74 (95% CI, 3.36-4.17) for men of African ancestry. Men of African ancestry were estimated to have a mean GRS that was 2.18-times higher (95% CI, 2.14-2.22), and men of East Asian ancestry 0.73-times lower (95% CI, 0.71-0.76), than men of European ancestry. These findings support the role of germline variation contributing to population differences in prostate cancer risk, with the GRS offering an approach for personalized risk prediction.